II-B08
| Code | Size | Price |
|---|
| TAR-T27591-5mg | 5mg | £1,171.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T27591-50mg | 50mg | £2,303.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T27591-100mg | 100mg | £3,042.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
II-B08 is a cell-permeable SHP2 inhibitor (IC50 = 5.5 ?M). II-B08 blocks growth factor stimulated ERK1/2 activation and hematopoietic progenitor proliferation.
CAS:
1143579-78-5
Formula:
C33H27N5O4
Molecular Weight:
557.61
Purity:
0.98
SMILES:
Cn1c(c(-c2cn(CCC(=O)Nc3ccc(cc3)-c3ccccc3)nn2)c2cc(C(O)=O)c(O)cc12)-c1ccccc1
References
1. Sharma N, Everingham S, Zeng LF, Zhang ZY, Kapur R, Craig AW. Oncogenic KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for disease progression in mice. Oncotarget. 2014 Aug 15;5(15):6130-41. PubMed PMID: 25026279; PubMed Central PMCID: PMC4171618.
2. Duan YQ, Ma Y, Wang XJ, Jin YY, Wang RL, Dong WL, Xu WR, Kong DX, Wang SQ. Design potential selective inhibitors for treating cancer by targeting the Src homology 2 (SH2) domain-containing phosphatase 2 (Shp2) with core hopping approach. Protein Pept Lett. 2014 Jun;21(6):556-63. PubMed PMID: 24364859.
3. Xu J, Zeng LF, Shen W, Turchi JJ, Zhang ZY. Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma. Biochem Biophys Res Commun. 2013 Oct 4;439(4):586-90. doi: 10.1016/j.bbrc.2013.09.028. Epub 2013 Sep 13. PubMed PMID: 24041688; PubMed Central PMCID: PMC3822432.
4. Zhang X, He Y, Liu S, Yu Z, Jiang ZX, Yang Z, Dong Y, Nabinger SC, Wu L, Gunawan AM, Wang L, Chan RJ, Zhang ZY. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). J Med Chem. 2010 Mar 25;53(6):2482-93. doi: 10.1021/jm901645u. PubMed PMID: 20170098; PubMed Central PMCID: PMC2842125.